Amish Chaturvedi is an experienced market access professional with 26 years of experience in the Pharmaceutical industry including in Pricing, Market access, Reimbursement and Policy across EU and JAPAC region. At EVERSANA, he leads Pricing and Market Access practice for the APAC region. As a practice lead, Amish leverages his vast experience to support pharmaceutical, medical devices and biotech companies build Value and Access strategy for Asia-Pacific region including for key markets like Japan, China, India, South Korea, Taiwan and Australia. Amish has extensive experience in developing and optimizing value communication in the local context to improve relevance and impact on payers. In addition, Amish supports clients optimize their access and reimbursement strategies at a regional level and guides the development of HTA submissions at country level.   Prior to joining EVERSANA, Amish spent 15 years in Policy and Market Access functions as therapy area lead for Abbvie and Janssen in above country and affiliate level roles.  Amish has hands-on experience managing reimbursement submissions to multiple HTA agencies. He has a deep understanding of access policies in key European and Asia-Pacific markets and HTA requirements across JAPAC,EU4 and the UK. He has worked across multiple therapy areas including Oncology, Immunology, Neuroscience, Infectious Diseases and Vaccines. Amish holds a B-Pharm degree, MBA degree (Australian National University) and Health Economics degree from London School of Economics (LSE).

Ann Single is the Coordinator for the Patient Voice Initiative, a multi-stakeholder patient-led not for profit working to ensure patients are seen, heard and valued in healthcare decision-making, especially in health technology assessment (HTA). She’s worked in patient involvement in HTA for more than 20 years, first directing it within Scotland’s HTA agency and then sharing and developing good practice in HTAi’s Patient and Citizen Involvement Interest Group. After Chairing this group of 300 multi-stakeholder members in 43 countries for four years, in 2023 she became its Outgoing Chair and HTAi’s first Vice President from the patient community sector. Ann co-edited the book Patient Involvement in Health Technology Assessment (2017) and is a faculty member member of the International Patient Advocacy Management Masters Course at Rome’s Catholic University (Università Cattolica del Sacro Cuore). Her must recent peer-reviewed paper considers cases of patients involved at the organisational level of HTA bodies. She currently serves as a consumer representative on the Australian Government’s HTA Policy and Methods Review Reference Committee.

Sam Pearson is Patient Advocacy Lead at AbbVie Australia and New Zealand. She works with teams across the business to ensure the patient and caregiver voice is at the heart of cross functional and strategic decision making. She works closely with patient advocacy groups to bring insights back to the business and works on collaborative initiatives which help to advance the standards of care, support access to medicines and provide education and support to patients. Sam has worked at AbbVie for six years across brand communications and patient advocacy, and has 15 years’ experience working in communications, public affairs and stakeholder engagement.

Stephen has more than 20 years’ experience in the innovative medicines industry. Currently Corporate Policy Lead at Sanofi, he has worked across public affairs, communications, and patient advocacy. Stephen has established strong relationships with various patient advocacy groups who represent the interests of Australians living with complex and chronic diseases like cancer and diabetes. He co-leads Sanofi’s Culture and Origins Employee Resource Group that is focused on delivering the company’s Innovate Reconciliation Action Plan.

Anne-Maree is passionate about the potential of innovative technologies to improve health outcomes. An engineer by trade, she also has a masters in public policy, and combines a thorough knowledge of product development with a strong understanding of the broader health and innovation policy landscape. She started her career at the medical device innovator Cochlear, has been the Operations Manager at health IT startup Humanetix, and also spent several years as Policy Manager at pharmaceutical company MSD. She is currently Head of Strategic Policy Implementation at Medicines Australia.